GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival

Aatur D. Singhi, Jon M. Davison, Haroon A. Choudry, James F. Pingpank, Steven A. Ahrendt, Matthew P. Holtzman, Amer H. Zureikat, Herbert J. Zeh, Lekshmi Ramalingam, Geeta Mantha, Marina Nikiforova, David L. Bartlett, Reetesh K. Pai

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We analyzed a series of 55 disseminated appendiceal mucinous neoplasms treated at our institution for GNAS and KRAS mutations in an attempt to correlate mutation status with clinicopathological findings and patient survival. GNAS mutations (p.R201H, c.602G>A and p.R201C, and c.602C>T) were identified in 17 (31%) of 55 of disseminated mucinous neoplasms and were found in 8 (35%) of 23 low-grade mucinous neoplasms, 7 (37%) of 19 high-grade mucinous adenocarcinomas lacking a signet ring cell component, and 2 (15%) of 13 high-grade mucinous adenocarcinomas with a signet ring cell component. All 7 mucinous adenocarcinomas composed of pure (>95%) signet ring cells harbored wild-type GNAS. There was no significant association between GNAS mutations and sex and age (both with P >.05) or between GNAS mutations and individual adverse histologic features including cytologic grade, destructive invasion, tumor cellularity, angiolymphatic invasion, perineural invasion, and signet ring cells (all with P >.05). KRAS mutations were identified in 22 (40%) of 55 disseminated mucinous neoplasms. GNAS-mutated disseminated appendiceal mucinous neoplasms more frequently harbored concurrent KRAS mutations compared with GNAS wild-type tumors (65% versus 29%, P =.018). GNAS mutations were not significantly associated with overall survival (both with P >.05). Only overall tumor grade was an independent predictor of overall survival in the multivariate analysis (P =.01). Our results indicate that GNAS mutations are frequently identified in both low-grade and high-grade disseminated appendiceal mucinous neoplasms indicating that GNAS mutation status cannot be used to distinguish between low-grade from high-grade appendiceal mucinous neoplasms.

Original languageEnglish (US)
Pages (from-to)1737-1743
Number of pages7
JournalHuman Pathology
Volume45
Issue number8
DOIs
StatePublished - Aug 2014
Externally publishedYes

Fingerprint

Appendiceal Neoplasms
Mutation
Survival
Mucinous Adenocarcinoma
Neoplasms
Cellular Structures

Keywords

  • Appendix
  • Disseminated peritoneal adenomucinosis
  • GNAS
  • Low-grade mucinous neoplasm
  • Mucinous adenocarcinoma
  • Peritoneal mucinous carcinomatosis
  • Pseudomyxoma peritonei

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Singhi, A. D., Davison, J. M., Choudry, H. A., Pingpank, J. F., Ahrendt, S. A., Holtzman, M. P., ... Pai, R. K. (2014). GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. Human Pathology, 45(8), 1737-1743. https://doi.org/10.1016/j.humpath.2014.04.018

GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. / Singhi, Aatur D.; Davison, Jon M.; Choudry, Haroon A.; Pingpank, James F.; Ahrendt, Steven A.; Holtzman, Matthew P.; Zureikat, Amer H.; Zeh, Herbert J.; Ramalingam, Lekshmi; Mantha, Geeta; Nikiforova, Marina; Bartlett, David L.; Pai, Reetesh K.

In: Human Pathology, Vol. 45, No. 8, 08.2014, p. 1737-1743.

Research output: Contribution to journalArticle

Singhi, AD, Davison, JM, Choudry, HA, Pingpank, JF, Ahrendt, SA, Holtzman, MP, Zureikat, AH, Zeh, HJ, Ramalingam, L, Mantha, G, Nikiforova, M, Bartlett, DL & Pai, RK 2014, 'GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival', Human Pathology, vol. 45, no. 8, pp. 1737-1743. https://doi.org/10.1016/j.humpath.2014.04.018
Singhi, Aatur D. ; Davison, Jon M. ; Choudry, Haroon A. ; Pingpank, James F. ; Ahrendt, Steven A. ; Holtzman, Matthew P. ; Zureikat, Amer H. ; Zeh, Herbert J. ; Ramalingam, Lekshmi ; Mantha, Geeta ; Nikiforova, Marina ; Bartlett, David L. ; Pai, Reetesh K. / GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. In: Human Pathology. 2014 ; Vol. 45, No. 8. pp. 1737-1743.
@article{2c0119be3f4d46889a4e73e707789ecf,
title = "GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival",
abstract = "We analyzed a series of 55 disseminated appendiceal mucinous neoplasms treated at our institution for GNAS and KRAS mutations in an attempt to correlate mutation status with clinicopathological findings and patient survival. GNAS mutations (p.R201H, c.602G>A and p.R201C, and c.602C>T) were identified in 17 (31{\%}) of 55 of disseminated mucinous neoplasms and were found in 8 (35{\%}) of 23 low-grade mucinous neoplasms, 7 (37{\%}) of 19 high-grade mucinous adenocarcinomas lacking a signet ring cell component, and 2 (15{\%}) of 13 high-grade mucinous adenocarcinomas with a signet ring cell component. All 7 mucinous adenocarcinomas composed of pure (>95{\%}) signet ring cells harbored wild-type GNAS. There was no significant association between GNAS mutations and sex and age (both with P >.05) or between GNAS mutations and individual adverse histologic features including cytologic grade, destructive invasion, tumor cellularity, angiolymphatic invasion, perineural invasion, and signet ring cells (all with P >.05). KRAS mutations were identified in 22 (40{\%}) of 55 disseminated mucinous neoplasms. GNAS-mutated disseminated appendiceal mucinous neoplasms more frequently harbored concurrent KRAS mutations compared with GNAS wild-type tumors (65{\%} versus 29{\%}, P =.018). GNAS mutations were not significantly associated with overall survival (both with P >.05). Only overall tumor grade was an independent predictor of overall survival in the multivariate analysis (P =.01). Our results indicate that GNAS mutations are frequently identified in both low-grade and high-grade disseminated appendiceal mucinous neoplasms indicating that GNAS mutation status cannot be used to distinguish between low-grade from high-grade appendiceal mucinous neoplasms.",
keywords = "Appendix, Disseminated peritoneal adenomucinosis, GNAS, Low-grade mucinous neoplasm, Mucinous adenocarcinoma, Peritoneal mucinous carcinomatosis, Pseudomyxoma peritonei",
author = "Singhi, {Aatur D.} and Davison, {Jon M.} and Choudry, {Haroon A.} and Pingpank, {James F.} and Ahrendt, {Steven A.} and Holtzman, {Matthew P.} and Zureikat, {Amer H.} and Zeh, {Herbert J.} and Lekshmi Ramalingam and Geeta Mantha and Marina Nikiforova and Bartlett, {David L.} and Pai, {Reetesh K.}",
year = "2014",
month = "8",
doi = "10.1016/j.humpath.2014.04.018",
language = "English (US)",
volume = "45",
pages = "1737--1743",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival

AU - Singhi, Aatur D.

AU - Davison, Jon M.

AU - Choudry, Haroon A.

AU - Pingpank, James F.

AU - Ahrendt, Steven A.

AU - Holtzman, Matthew P.

AU - Zureikat, Amer H.

AU - Zeh, Herbert J.

AU - Ramalingam, Lekshmi

AU - Mantha, Geeta

AU - Nikiforova, Marina

AU - Bartlett, David L.

AU - Pai, Reetesh K.

PY - 2014/8

Y1 - 2014/8

N2 - We analyzed a series of 55 disseminated appendiceal mucinous neoplasms treated at our institution for GNAS and KRAS mutations in an attempt to correlate mutation status with clinicopathological findings and patient survival. GNAS mutations (p.R201H, c.602G>A and p.R201C, and c.602C>T) were identified in 17 (31%) of 55 of disseminated mucinous neoplasms and were found in 8 (35%) of 23 low-grade mucinous neoplasms, 7 (37%) of 19 high-grade mucinous adenocarcinomas lacking a signet ring cell component, and 2 (15%) of 13 high-grade mucinous adenocarcinomas with a signet ring cell component. All 7 mucinous adenocarcinomas composed of pure (>95%) signet ring cells harbored wild-type GNAS. There was no significant association between GNAS mutations and sex and age (both with P >.05) or between GNAS mutations and individual adverse histologic features including cytologic grade, destructive invasion, tumor cellularity, angiolymphatic invasion, perineural invasion, and signet ring cells (all with P >.05). KRAS mutations were identified in 22 (40%) of 55 disseminated mucinous neoplasms. GNAS-mutated disseminated appendiceal mucinous neoplasms more frequently harbored concurrent KRAS mutations compared with GNAS wild-type tumors (65% versus 29%, P =.018). GNAS mutations were not significantly associated with overall survival (both with P >.05). Only overall tumor grade was an independent predictor of overall survival in the multivariate analysis (P =.01). Our results indicate that GNAS mutations are frequently identified in both low-grade and high-grade disseminated appendiceal mucinous neoplasms indicating that GNAS mutation status cannot be used to distinguish between low-grade from high-grade appendiceal mucinous neoplasms.

AB - We analyzed a series of 55 disseminated appendiceal mucinous neoplasms treated at our institution for GNAS and KRAS mutations in an attempt to correlate mutation status with clinicopathological findings and patient survival. GNAS mutations (p.R201H, c.602G>A and p.R201C, and c.602C>T) were identified in 17 (31%) of 55 of disseminated mucinous neoplasms and were found in 8 (35%) of 23 low-grade mucinous neoplasms, 7 (37%) of 19 high-grade mucinous adenocarcinomas lacking a signet ring cell component, and 2 (15%) of 13 high-grade mucinous adenocarcinomas with a signet ring cell component. All 7 mucinous adenocarcinomas composed of pure (>95%) signet ring cells harbored wild-type GNAS. There was no significant association between GNAS mutations and sex and age (both with P >.05) or between GNAS mutations and individual adverse histologic features including cytologic grade, destructive invasion, tumor cellularity, angiolymphatic invasion, perineural invasion, and signet ring cells (all with P >.05). KRAS mutations were identified in 22 (40%) of 55 disseminated mucinous neoplasms. GNAS-mutated disseminated appendiceal mucinous neoplasms more frequently harbored concurrent KRAS mutations compared with GNAS wild-type tumors (65% versus 29%, P =.018). GNAS mutations were not significantly associated with overall survival (both with P >.05). Only overall tumor grade was an independent predictor of overall survival in the multivariate analysis (P =.01). Our results indicate that GNAS mutations are frequently identified in both low-grade and high-grade disseminated appendiceal mucinous neoplasms indicating that GNAS mutation status cannot be used to distinguish between low-grade from high-grade appendiceal mucinous neoplasms.

KW - Appendix

KW - Disseminated peritoneal adenomucinosis

KW - GNAS

KW - Low-grade mucinous neoplasm

KW - Mucinous adenocarcinoma

KW - Peritoneal mucinous carcinomatosis

KW - Pseudomyxoma peritonei

UR - http://www.scopus.com/inward/record.url?scp=84904621566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904621566&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2014.04.018

DO - 10.1016/j.humpath.2014.04.018

M3 - Article

C2 - 24925222

AN - SCOPUS:84904621566

VL - 45

SP - 1737

EP - 1743

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 8

ER -